# Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

> **NCT04439006** · PHASE1 · COMPLETED · sponsor: **Jennifer Woyach** · enrollment: 10 (actual)

## Conditions studied

- Aplastic Anemia
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Monoclonal B-Cell Lymphocytosis
- Monoclonal Gammopathy of Undetermined Significance
- Myelodysplastic Syndrome
- Symptomatic COVID-19 Infection Laboratory-Confirmed

## Interventions

- **OTHER:** Best Practice
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT04439006
- **Lead sponsor:** Jennifer Woyach
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-23
- **Primary completion:** 2022-09-20
- **Final completion:** 2022-09-20
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439006, "Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04439006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*